These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12032698)

  • 21. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic genetic transfer of p21WAF-1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex.
    Liu X; Tian PK; Ju DW; Zhang MH; Yao M; Cao XT; Gu JR
    Cancer Gene Ther; 2003 Jul; 10(7):529-39. PubMed ID: 12833133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene.
    Rasmussen H; Rasmussen C; Lempicki M; Durham R; Brough D; King CR; Weichselbaum R
    Cancer Gene Ther; 2002 Nov; 9(11):951-7. PubMed ID: 12386834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
    Messerschmidt SK; Musyanovych A; Altvater M; Scheurich P; Pfizenmaier K; Landfester K; Kontermann RE
    J Control Release; 2009 Jul; 137(1):69-77. PubMed ID: 19306900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
    Zhang W; Yang H; Wang Z; Jim X
    Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer gene therapy using a novel secretable trimeric TRAIL.
    Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
    Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression.
    Aigner A; Fischer D; Merdan T; Brus C; Kissel T; Czubayko F
    Gene Ther; 2002 Dec; 9(24):1700-7. PubMed ID: 12457284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.
    Xiao F; Wei Y; Yang L; Zhao X; Tian L; Ding Z; Yuan S; Lou Y; Liu F; Wen Y; Li J; Deng H; Kang B; Mao Y; Lei S; He Q; Su J; Lu Y; Niu T; Hou J; Huang MJ
    Gene Ther; 2002 Sep; 9(18):1207-13. PubMed ID: 12215887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
    Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
    Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
    Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
    Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor regression by targeted gene delivery to the neovasculature.
    Hood JD; Bednarski M; Frausto R; Guccione S; Reisfeld RA; Xiang R; Cheresh DA
    Science; 2002 Jun; 296(5577):2404-7. PubMed ID: 12089446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
    Schmitz V; Vilanueva H; Raskopf E; Hilbert T; Barajas M; Dzienisowicz C; Gorschlüter M; Strehl J; Rabe C; Sauerbruch T; Prieto J; Caselmann WH; Qian C
    Gene Ther; 2006 Aug; 13(16):1198-205. PubMed ID: 16617302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
    Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
    Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway.
    Zins K; Abraham D; Sioud M; Aharinejad S
    Cancer Res; 2007 Feb; 67(3):1038-45. PubMed ID: 17283136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth inhibition of the pulmonary metastatic tumors by systemic delivery of the p27 kip1 gene using lyophilized lipid-polycation-DNA complexes.
    Sun X; Zhang HW; Zhang ZR
    J Gene Med; 2009 Jun; 11(6):535-44. PubMed ID: 19326369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression.
    Mohr A; Henderson G; Dudus L; Herr I; Kuerschner T; Debatin KM; Weiher H; Fisher KJ; Zwacka RM
    Gene Ther; 2004 Mar; 11(6):534-43. PubMed ID: 14999225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
    Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
    J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid.
    Hatakeyama H; Akita H; Kogure K; Oishi M; Nagasaki Y; Kihira Y; Ueno M; Kobayashi H; Kikuchi H; Harashima H
    Gene Ther; 2007 Jan; 14(1):68-77. PubMed ID: 16915290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.
    Liu XY; Qiu SB; Zou WG; Pei ZF; Gu JF; Luo CX; Ruan HM; Chen Y; Qi YP; Qian C
    Mol Ther; 2005 Apr; 11(4):531-41. PubMed ID: 15771956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.